Clinical Trials
Clinical Trials
shadow

Title # of Patients Sites Objective Status
ANGEL Phase I Trial 5 Patients Hospital Angeles Phase I study to assess safety and feasibility of AdipoCell™ Enrollment complete
MARVEL (Phase II/III Clinical Trial) MARVEL Part 1: 20 Patients (completed) MARVEL Part 2: 133 Patients Up to 35 sites in the United States Designed to be a double blind, randomized, placebo controlled multi-center trial to evaluate the safety and efficacy of MyoCell® delivered via MyoStar® MyoCell® implantation procedure completed on first patient in October 2007. MARVEL part 1 data on the first 20 patients analyzed and presented at the Heart Failure Society of America (HFSA) Meeting in 2009. Data displayed overall positive clinical result
MIRROR (Phase III clinical trial) 126 Up to 35 sites OUS Designed to be a double blind, randomized, placebo controlled multi-center trial to evaluate the safety and efficacy of MyoCell® delivered via MyoCath® Currently enrolling
MYOHEART (Phase I Clinical Trial) 20 Five sites in the United States Trials have been designed to test the safety and efficacy of MyoCell in treating patients with severe, chronic damage to the heart. Trial commenced in 2003; treatment of all 20 patients completed in October 2006; final twelve-month data presented in January 2008.
REGEN (Phase I Clinical Trial) 15 3 Sites in US Designed to test the safety and effectiveness of a composition of muscle stem cells that have been gene-modified to induce a greater than usual release of the SDF-1 protein Approval received in July 2009 from the FDA to move forward with the trail.